Do We Need New Therapies For Diabetes?
Diabetes Research - Open Journal · 2015
DOI: 10.17140/droj-1-112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Research - Open Journal, 2015. Verfasst von Dimiter Dimitrov. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetes research and practice cluster (drug developers, payers, regulators and physicians) often (and especially in recent times) question the need of new therapies. Why would we need new therapies nowadays, when we have 9 classes (insulins, sulfonylureas, biguanides, meglitdes, thiazolidnediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists),1 rapidly increasing number of biosimilars2 and uncountable number of generics? Reasonable question. Does it make sense to invest billions of dollars in messy global cardiovascular outcomes trials (as requested by diabetes drug development guidelines3) or to play love attraction games with payers4 so they “fall in love” with the “new” pill (most often combo with the good old metformin)?Well….I believe someone is missing in this picture. Obviously, those four players forget the Patient. And the ability to ask a bit more simple and rational questions, such as “Do we have adequate glycemic control of diabetes in the presence of all those therapies”?
Zitieren
APA
Dimitrov, D. (2015). Do We Need New Therapies For Diabetes?. Diabetes Research - Open Journal. https://doi.org/10.17140/droj-1-112
Vancouver
Dimitrov D. Do We Need New Therapies For Diabetes?. Diabetes Research - Open Journal. 2015. doi:10.17140/droj-1-112
BibTeX
@article{Dimitrov2015,
author = {Dimitrov, Dimiter},
title = {Do We Need New Therapies For Diabetes?},
journal = {Diabetes Research - Open Journal},
year = {2015},
doi = {10.17140/droj-1-112}
}
EUVIMED